

1 Dalmore Drive,  
Scoresby,  
Victoria 3179  
AUSTRALIA  
T: +61 (0)3 9763-1287  
F: +61 (0)3 9763-2817  
[www.generabiosystems.com](http://www.generabiosystems.com)

**Thursday 27 September 2018**

**ASX Announcement – GENERA BIOSYSTEMS LIMITED (ASX: GBI)  
GENERA – CHANGE OF DIRECTOR’S INTEREST NOTICES X2**

---

Genera Biosystems Limited (ASX:GBI) (‘Genera’ or ‘the Company’) attaches an Appendix 3Y for Mr Lou Panaccio and Mr David Symons in relation to the lapse of fully paid ordinary shares pursuant to a Call Option Deed.

The Company notes that the notice was not lodged within the requisite time frame due to an administrative oversight. The lapse was identified as part of the finalisation of Genera’s full year audit. The notice was prepared and lodged as soon as practicable once the Company became aware of the oversight.

The Company and Directors are aware of the requirements under ASX Listing Rule 3.19A and 3.19B. The administrative oversight has not affected the Company’s current arrangement for ensuring timely notification in accordance with the listing rules and the Company is confident that the arrangements it currently has in place are adequate and doesn’t believe that any additional steps are required to ensure ongoing compliance with listing rule 3.19B.

For further information please contact:

Mr Richard Hannebery  
Chief Executive Officer  
Genera Biosystems Limited  
Telephone: +61 (0)3 9763 1287  
[www.generabiosystems.com.au](http://www.generabiosystems.com.au)

**About Genera Biosystems** : Genera Biosystems Limited (“GBI”) is an Australian Securities Exchange listed molecular diagnostics company, which develops, manufactures and distributes advanced PCR molecular diagnostics tests.

Genera’s single-well high multiplex AmpaSand® testing platform can detect up to 125 target analytes in a single-well of a reaction plate. Unlike traditional real-time PCR approaches, AmpaSand® single-well multiplex tests when run on a seamlessly integrated flow cytometry and liquid handling system can provide unparalleled throughput capability and cost efficiency for high volume pathology laboratories qualitative molecular testing needs.<sup>1</sup>

Genera manufactures products in its Australian Therapeutics Goods Administration certified manufacturing facility in Scoresby, Victoria, Australia.

PapType®, an ARTG listed and CE-marked MDx test, simultaneously detects and identifies 14 high-risk types of HPV and 2 low risk HPV types in a single-well. These high-risk HPV types are responsible for 99.7% of all cases of cervical cancer.

In addition to PapType®, Genera has also commercialized and gained ARTG listing and CE mark for RTIplex™, a single-well multiplex MDx that identifies 15 common upper respiratory tract pathogens, including Influenza A & B, as well as 10 other viral and 3 bacterial disease-causing microbial targets.

Genera’s development pipeline includes a new 8-plex sexually transmitted infections panel that is expected to be available in the 2<sup>nd</sup> half of 2018, with plans to broaden the AmpaSand® test menu further to 6 highly competitive single-well multiplex MDx assays by 2019.

PapType®, RTIplex™, and the tests in development, employ the AmpaSand® biochemistry as well as Genera’s proprietary ARTG listed and CE-IVD marked QPlots™ automated analytical and reporting software that is compatible with most Laboratory Information Management Systems (‘LIMS’).

All the components of the Genera MDx system, including AmpaSand® and QPlots™, have been optimized to run on Beckman Coulter's innovative CytoFLEX™ flow cytometry system.

---

<sup>1</sup> All ‘plate based’ Real Time PCR platforms can ‘multiplex’ up to 4 targets per well assuming 4 available channels of a Real Time PCR instrument. To multiplex greater than 4 target analytes in a test most platforms require use of additional wells of a plate to test for the additional target analytes. As such commercially, their multiplexing capability is restricted due to a direct trade-off with volume throughput per plate (96 or 384 well). Genera’s AmpaSand® technology facilitates the multiplexing of up to ~125 target analytes **in a single-well** of a plate. On a like for like basis depending on the number of target analytes detected in a multiplex assay Genera’s AmpaSand® technology facilitates > 4X relative volume throughput. High volume throughput is a key commercial consideration for all large pathology labs undertaking HPV and STI testing.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

Name of entity	GENERA BIOSYSTEMS LIMITED (ASX:GBI)
ABN	69 098 663 837

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David Symons
Date of last notice	20 December 2017

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	4 May 2018
No. of securities held prior to change	1,163,808 fully paid ordinary shares.  358,334 fully paid ordinary shares pursuant to Call Option Deed referred to in Part 2 below  862,930 options exercisable at \$0.25 (25 cents) on or before 20 December 2020.
Class	Fully paid ordinary shares
Number acquired	Nil
Number disposed	358,334 fully paid ordinary shares pursuant to Call Option Deed referred to in Part 2 below
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil – expiry of Call option unexercised

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	1,163,808 fully paid ordinary shares.  862,930 options exercisable at \$0.25 (25 cents) on or before 20 December 2020.
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Lapse of 358,334 fully paid ordinary shares pursuant to Call Option Deed referred to in Part 2 below

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Call Option deed
<b>Nature of interest</b>	The Call Option Deed confers the right for David Symons (or his nominee) to call the transfer of 358,334 Ordinary Shares in Genera at an exercise price of \$0.21 per Share anytime up to 4 May 2018.
<b>Name of registered holder (if issued securities)</b>	Como Group Holdings Pty Limited <ATF The Como Trust>
<b>Date of change</b>	4 May 2018
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	358,334 fully paid ordinary shares
<b>Interest acquired</b>	Nil
<b>Interest disposed</b>	358,334 fully paid ordinary shares
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	Nil – expiry of Call option unexercised
<b>Interest after change</b>	Refer to Part 1

**Part 3 – +Closed period**

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

Name of entity	GENERA BIOSYSTEMS LIMITED (ASX:GBI)
ABN	69 098 663 837

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Lou Panaccio
Date of last notice	20 December 2017

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<b>Indirect (1)</b> Shares held by Tercus Pty Ltd <Panaccio Super Fund A/C>, an entity in which Lou Panaccio has an interest.
Date of change	4 May 2018
No. of securities held prior to change	<b>Direct</b> 80,000 fully paid ordinary shares  <b>Indirect(1)</b> 840,283 fully paid ordinary shares  1,975,000 fully paid ordinary shares pursuant to Call Option Deed referred to in Part 2 below.  1,950,972 options exercisable at \$0.25 (25 cents) on or before 20 December 2020.
Class	Fully paid ordinary shares
Number acquired	Nil
Number disposed	1,975,000 fully paid ordinary shares pursuant to Call Option Deed referred to in Part 2 below.

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil – expiry of Call option unexercised
<b>No. of securities held after change</b>	<b>Direct</b> 80,000 fully paid ordinary shares  <b>Indirect(1)</b> 840,283 fully paid ordinary shares  1,950,972 options exercisable at \$0.25 (25 cents) on or before 20 December 2020.
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Lapse of 1,975,000 fully paid ordinary shares pursuant to Call option Deed referred to in part 2 below

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	Call Option Deed
<b>Nature of interest</b>	The Call Option Deed confers the right for Lou Panaccio (or his nominee) to call the transfer of 1,975,000 fully paid ordinary shares in Genera at an exercise price of \$0.21 per Share anytime up to 4 May 2018.
<b>Name of registered holder (if issued securities)</b>	Como Group Holdings Pty Limited <ATF The Como Trust>
<b>Date of change</b>	4 May 2018
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	1,975,000 fully paid ordinary shares
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	1,975,000 fully paid ordinary shares
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	Nil – expiry of Call option unexercised
<b>Interest after change</b>	Refer to Part 1

**Part 3 – +Closed period**

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

If prior written clearance was provided, on what date was this provided?	N/A
--	-----

---

+ See chapter 19 for defined terms.